Ebronucimab
- Generic Name
- Ebronucimab
- Brand Names
- 伊喜宁
Akeso's Gumokimab (IL-17 mAb) Application Accepted for Psoriasis Treatment in China
• Akeso's gumokimab, an IL-17 targeting monoclonal antibody, has its NDA accepted by China's NMPA for treating moderate to severe plaque psoriasis.
• Clinical trials showed gumokimab's rapid efficacy, with PASI 75 response rates approaching 96% at week 12 and sustained improvement over 52 weeks.
• Safety profiles of gumokimab were comparable to placebo, indicating good tolerability, which addresses the need for safer psoriasis treatments.
• Akeso aims to meet diverse patient needs by combining gumokimab with other drugs like ebronucimab, enhancing their autoimmune disease product synergy.
Homozygous Familial Hypercholesterolemia Treatment Market to Surge by 2034
The Homozygous Familial Hypercholesterolemia (HoFH) treatment market, valued at approximately USD 108 million in 2022, is expected to grow significantly by 2034. With key players like Arrowhead Pharmaceutical and Novartis leading the charge, the market is set to benefit from increased disease prevalence, awareness, and the launch of innovative therapies. The FDA's recent approval of Evkeeza for children marks a pivotal advancement in HoFH treatment.
Cadonilimab Plus Chemotherapy Shows Survival Benefit in Advanced Gastric Cancer
• Phase III trial data published in *Nature Medicine* highlights the benefits of cadonilimab combined with chemotherapy for advanced gastric cancer.
• The study showed significant improvement in overall survival, regardless of PD-L1 expression levels in patients.
• Cadonilimab, a PD-1/CTLA-4 bispecific antibody, addresses limitations of PD-1 inhibitors in PD-L1 low-expressing gastric cancer.
• Approved in September 2024, cadonilimab is now used in clinical practice, offering a new immunotherapy option.
Akeso's Bispecific Antibodies Show Promise in Lung and Colorectal Cancers
• Akeso's ivonescimab, a PD-1/VEGF bispecific antibody, gains approval in China for EGFR-mutated NSCLC and shows significant benefits in PD-L1 positive NSCLC compared to pembrolizumab.
• Ligufalimab, a CD47 monoclonal antibody, enters Phase III trials for head and neck squamous cell carcinoma, marking the first CD47 mAb in Phase III for solid tumors.
• Ivonescimab, combined with FOLFOXIRI, demonstrates high anti-tumor activity in first-line treatment of MSS/pMMR metastatic colorectal cancer, with a 88.2% objective response rate.
• Akeso is advancing a diverse pipeline of innovative therapies, including bispecific antibodies and ADCs, with multiple Phase III trials underway across various cancer types.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath